{"id":2830,"date":"2026-08-24T23:46:48","date_gmt":"2026-08-24T23:46:48","guid":{"rendered":"https:\/\/officialcorepeptides.brandloom.net\/en\/?post_type=product&p=2830"},"modified":"2026-08-24T23:46:48","modified_gmt":"2026-08-24T23:46:48","slug":"buy-foxo4-dri-10mg-in-switzerland","status":"publish","type":"product","link":"https:\/\/officialcorepeptides.ch\/en\/product\/buy-foxo4-dri-10mg-in-switzerland\/","title":{"rendered":"FOXO4-DRI (10MG)"},"content":{"rendered":"

What Is FOXO4-DRI and Why Buy It for Research?<\/strong><\/h2>\n

Buy FOXO4-DRI 10mg in Switzerland for research into cellular senescence, senolytic mechanisms, and aging pathways. Specifically, FOXO4-DRI (also known as FOXO4 D-Retro-Inverso peptide) is a synthetic 46-amino acid cell-permeable peptide antagonist designed to selectively induce apoptosis in senescent cells. The peptide features a D-retro-inverso (DRI) configuration, meaning it consists entirely of D-amino acid residues arranged in a retro-inverso sequence, which confers enhanced stability and resistance to proteolytic degradation.<\/p>\n

Researchers first described FOXO4-DRI in a landmark 2017 study by Baar and colleagues, published in Cell, demonstrating its ability to selectively eliminate senescent cells and restore tissue homeostasis in response to chemotoxicity and aging. Subsequently, beneficial effects of FOXO4-DRI have been demonstrated in various age-related models. In scientific research, FOXO4-DRI serves as a molecular tool for studying cellular senescence, apoptosis pathways, and senolytic interventions. Furthermore, Core Peptides supplies FOXO4-DRI as a lyophilized powder in a 10mg format exclusively for laboratory use. Therefore, researchers seeking to source this compound for their work will find it readily available when they buy FOXO4-DRI 10mg in Switzerland.<\/p>\n

FOXO4-DRI Research Overview: Buy FOXO4-DRI 10mg in Switzerland for Senolytic Studies<\/strong><\/h2>\n

Centrally, research into FOXO4-DRI has focused on its function as a senolytic agent that selectively targets and eliminates senescent cells. Cellular senescence is a hallmark of aging characterized by irreversible growth arrest and the secretion of pro-inflammatory factors collectively known as the senescence-associated secretory phenotype (SASP). The accumulation of senescent cells contributes to age-related functional decline and various diseases.<\/p>\n

FOXO4-DRI targets the FOXO4-p53 axis, which researchers have identified as pivotal in maintaining the viability of senescent cells. The peptide competitively disrupts the interaction between FOXO4 and p53, thereby facilitating the nuclear export of phosphorylated p53 and inducing apoptosis in senescent cells. This mechanism activates the p53\/BCL-2\/Caspase-3 signaling pathway to promote selective apoptosis of senescent cells.<\/p>\n

Notably, structural studies have revealed that the disordered FOXO4-DRI binds to the disordered p53 transactivation domain 2 (p53TAD2) and forms a transiently folded complex. Furthermore, p53 phosphorylation enhances the affinity for both FOXO4 and FOXO4-DRI. Accordingly, researchers who buy FOXO4-DRI 10mg in Switzerland from Core Peptides can support their investigations into cellular senescence, senolytic mechanisms, and aging pathways.<\/p>\n

How Does FOXO4-DRI Work in Research?<\/strong><\/h2>\n

Mechanistically, FOXO4-DRI’s proposed action involves functioning as a cell-permeable peptide antagonist that disrupts the FOXO4-p53 interaction in senescent cells. The peptide operates through a well-characterized mechanism involving several key steps.<\/p>\n

Disruption of FOXO4-p53 Interaction<\/strong><\/h3>\n

FOXO4-DRI competitively inhibits the binding of FOXO4 to p53 in senescent cells. In senescent cells, the FOXO4-p53 interaction prevents p53 from inducing apoptosis, thereby maintaining cell viability. By disrupting this interaction, FOXO4-DRI releases p53 from FOXO4 sequestration.<\/p>\n

Nuclear Export of Phosphorylated p53<\/strong><\/h3>\n

Following FOXO4-p53 disruption, FOXO4-DRI promotes the nuclear export of phosphorylated p53. This nuclear exclusion is a critical step in the senolytic mechanism, as it allows p53 to engage pro-apoptotic pathways in the cytoplasm. Studies have demonstrated that FOXO4-DRI facilitates the nuclear exclusion of upregulated p53-serine 15 phosphorylation.<\/p>\n

Activation of Apoptotic Pathways<\/strong><\/h3>\n

Once in the cytoplasm, phosphorylated p53 triggers the activation of the p53\/BCL-2\/Caspase-3 signaling pathway. This cascade involves the upregulation of BAX and activation of cleaved caspase-3, ultimately leading to apoptosis of senescent cells. Studies have shown that FOXO4-DRI treatment increases the apoptosis rate from 10% to 27% in senescent Leydig cells.<\/p>\n

D-Retro-Inverso Configuration<\/strong><\/h3>\n

FOXO4-DRI consists entirely of D-amino acid residues arranged in a retro-inverso sequence. This DRI configuration provides several advantages for research applications, including enhanced stability and resistance to proteolytic degradation, which allows for more consistent experimental results.<\/p>\n

Why Is FOXO4-DRI Studied in Switzerland?<\/strong><\/h2>\n

Primarily, researchers study FOXO4-DRI because it represents a well-characterized senolytic peptide that enables investigation of cellular senescence, apoptosis pathways, and aging mechanisms. In fact, this compound offers a focused tool for studying the molecular mechanisms underlying senescent cell clearance, tissue homeostasis, and age-related dysfunction.<\/p>\n

Research has demonstrated FOXO4-DRI’s relevance across multiple domains. Injection of FOXO4-DRI in both naturally aged and induced aging mice effectively suppressed aortic aging and improved aortic function. Additionally, FOXO4-DRI alleviates endothelial cell senescence induced by oxygen-glucose deprivation, thereby enhancing endothelial cell function. The peptide has also been shown to improve spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells.<\/p>\n

Furthermore, FOXO4-DRI induces apoptosis in keloid senescent fibroblasts by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. The peptide has demonstrated efficacy in selectively removing senescent cells from in vitro expanded human chondrocytes. Ultimately, researchers who buy FOXO4-DRI 10mg in Switzerland gain access to a comprehensive research tool for investigating cellular senescence, senolytic mechanisms, and aging pathways.<\/p>\n

FOXO4-DRI Research Areas in Laboratory Studies<\/strong><\/h2>\n\n\n\n\n\n\n\n\n\n\n\n
Research Area<\/th>\nFocus<\/th>\nEvidence Level<\/th>\n<\/tr>\n<\/thead>\n
Cellular Senescence<\/td>\nSenescent cell clearance, SASP modulation, senescence markers (p16, p21, p53)<\/td>\nMechanistic \/ In Vitro \/ In Vivo<\/td>\n<\/tr>\n
Senolytic Research<\/td>\nSelective apoptosis of senescent cells, senolytic drug development<\/td>\nPreclinical<\/td>\n<\/tr>\n
Vascular Aging<\/td>\nEndothelial cell senescence, aortic aging suppression, vascular function<\/td>\nAnimal \/ Preclinical<\/td>\n<\/tr>\n
Aging and Longevity<\/td>\nAge-related dysfunction, tissue homeostasis, lifespan extension<\/td>\nPreclinical<\/td>\n<\/tr>\n
Apoptosis Signaling<\/td>\np53\/BCL-2\/Caspase-3 pathway, nuclear exclusion of p53, BAX activation<\/td>\nMechanistic \/ In Vitro<\/td>\n<\/tr>\n
Reproductive Aging<\/td>\nSpermatogenesis, Leydig cell senescence, testosterone secretion<\/td>\nPreclinical<\/td>\n<\/tr>\n
Cartilage and Joint Health<\/td>\nChondrocyte senescence, osteoarthritis models, cartilage regeneration<\/td>\nIn Vitro \/ Preclinical<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

FOXO4-DRI Compared With Related Research Compounds<\/strong><\/h2>\n\n\n\n\n\n\n\n\n
Compound<\/th>\nResearch Focus<\/th>\nMechanism \/ Target<\/th>\nKey Difference<\/th>\n<\/tr>\n<\/thead>\n
FOXO4-DRI<\/td>\nCellular senescence, senolytic research, apoptosis<\/td>\nFOXO4-p53 disruption, p53 nuclear export<\/td>\n46-amino acid D-retro-inverso peptide; selective senolytic<\/td>\n<\/tr>\n
Dasatinib + Quercetin<\/td>\nSenolytic research, aging<\/td>\nMultiple pathways (D+Q combination)<\/td>\nSmall molecule drug combination; different mechanism<\/td>\n<\/tr>\n
Navitoclax (ABT-263)<\/td>\nSenolytic research, cancer<\/td>\nBCL-2\/BCL-xL inhibition<\/td>\nSmall molecule; BCL-2 inhibitor; broader effects<\/td>\n<\/tr>\n
Epithalon (AEDG)<\/td>\nPineal gland, telomerase activation, anti-aging<\/td>\nTelomerase activation, histone binding<\/td>\nTetrapeptide; different mechanism; pineal-specific<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Comparatively, FOXO4-DRI differs from other senolytic compounds in its mechanism and peptide-based approach. On the one hand, FOXO4-DRI is a D-retro-inverso peptide that specifically targets the FOXO4-p53 interaction in senescent cells. On the other hand, Dasatinib + Quercetin is a small molecule combination with broader mechanisms of action. In contrast, Navitoclax is a BCL-2 inhibitor with different senolytic properties, while Epithalon focuses on telomerase activation rather than senescent cell clearance.<\/p>\n

Research Applications for FOXO4-DRI in Switzerland<\/strong><\/h2>\n

Scientists have investigated FOXO4-DRI across several research domains:<\/p>\n